RecruitingNot ApplicableNCT02361554

Deep Brain Stimulation in Treatment Resistant Schizophrenia


Sponsor

Johns Hopkins University

Enrollment

6 participants

Start Date

Mar 1, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this pilot study is to investigate the use of deep brain stimulation (DBS) of the substantia nigra pars reticulata (SNr) in subjects with treatment-resistant schizophrenia. There is a subset of patients with schizophrenia who continue to have persistent psychotic symptoms (auditory hallucinations and delusions) despite multiple adequate medication trials with antipsychotic medications including clozapine. There are currently no available treatments for such patients who generally have poor function and are chronically disabled, unable to work, live independently or have meaningful social relationships. Neuroimaging studies in patients with schizophrenia have revealed information about pathological neural circuits that could be suitable targets using deep brain stimulation. Although not yet tested in patients with schizophrenia, DBS is in early phase clinical trials in other psychiatric disorders. This pilot study will investigate the use of DBS in treatment-resistant schizophrenia subjects who have exhausted all other therapeutic alternatives but continue to have persistent disabling psychotic symptoms. Of note, DBS is not FDA approved for use in patients with schizophrenia. The method will be similar to that used in subthalamic nucleus stimulation in patients with Parkinson's Disease. However, the electrode will be advanced slightly inferior into the SNr, a major outflow nucleus of the basal ganglia, with the intention of causing local inhibition of SNr outflow resulting in disinhibition of the mediodorsal nucleus (MDN) of the thalamus. Hypofunction of the MDN has been implicated in the pathophysiology of schizophrenia in post-mortem as well as multiple structural and functional imaging studies. Evidence suggests that dysfunction of the MD is implicated in both positive and cognitive symptoms (such as working memory impairment) in schizophrenia. Frequent monitoring and clinical assessment with psychiatric scales will be used to monitor treatment response.


Eligibility

Min Age: 22 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing deep brain stimulation — a procedure where small electrodes are surgically placed in the brain to deliver electrical signals — as a treatment for severe, treatment-resistant schizophrenia. **You may be eligible if...** - You are 22 years of age or older - You have a confirmed diagnosis of schizophrenia or schizoaffective disorder - Your condition has been treatment-resistant for at least one year, meaning persistent hallucinations (hearing voices) or delusions despite trying multiple medications - You have tried and failed at least three different antipsychotic medications **You may NOT be eligible if...** - You have a history of drug or alcohol dependency - You have a serious medical condition that increases the risk of surgery - You are pregnant or breastfeeding - You have had a brain injury or other neurological condition that could confound the results - You have a pacemaker or other implanted device Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEMedtronic Percept with SensSight Deep Brain Stimulation System

Placement of Deep brain stimulation System for treatment of chronic auditory hallucinations in treatment-resistant schizophrenia


Locations(1)

The Johns Hopkins Hospital

Baltimore, Maryland, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02361554


Related Trials